<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="17711">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02876328</url>
  </required_header>
  <id_info>
    <org_study_id>C15-33</org_study_id>
    <secondary_id>PREVACEBL3005</secondary_id>
    <nct_id>NCT02876328</nct_id>
  </id_info>
  <brief_title>Partnership for Research on Ebola VACcinations</brief_title>
  <acronym>PREVAC</acronym>
  <official_title>Partnership for Research on Ebola VACcinations (PREVAC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Liberia-US Clinical Trials Partnership Program, Partnership for Research on Ebola Virus in Liberia Project (PREVAIL)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>London School of Hygiene &amp; Tropical Medicine (LSHTM)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and immunogenicity of three vaccine
      strategies that may prevent Ebola virus disease (EVD) events in children and adults.
      Participants will receive either the Ad26.ZEBOV (rHAd26) vaccine with a MVA-BN-Filo (MVA)
      boost, or the rVSVΔG-ZEBOV-GP (rVSV) vaccine with or without boosting, or placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the safety and immunogenicity of two Ebola virus
      disease (EVD) vaccines, Ad26.ZEBOV (rHAd26) and rVSVΔG-ZEBOV-GP (rVSV), in children and
      adults. These vaccines will be studied using three different strategies: the rHAd26 vaccine
      plus a MVA-BN-Filo (MVA) boost, and the rVSV vaccine with or without boosting.

      During the initial phase of the study, people older than 12 years of age will be enrolled.
      At Day 0 (study entry), participants will be randomly assigned to receive the Ad26.ZEBOV
      vaccine or placebo. At Day 56, participants who received the Ad26.ZEBOV vaccine will receive
      an MVA boost and participants who received placebo will receive placebo again.

      When additional safety data for the current lot of the rVSV vaccine becomes available from
      an ongoing trial in the United States, or when a new lot of the rVSV vaccine becomes
      available, the trial will be expanded to include the rVSV vaccine strategies and matching
      placebo.

      Once this occurs, people 1 year of age or older will be randomized into five groups: the two
      groups described above, the rVSV vaccine with or without boosting, or a second placebo
      group. At Day 56, participants who received the rVSV vaccine will receive either an rVSV
      boost or placebo and participants who received placebo will receive placebo again.

      Additional study visits will occur on Days 7, 14, 28, and 63, and at Months 3, 6, and 12.
      Study follow-up may continue for up to 5 years. Study visits may include blood collection
      and other assessments.

      Some participants may take part in substudies, which will include blood or saliva
      collection.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2017</start_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Ebola virus glycoprotein (GP-EBOV) antibody response</measure>
    <time_frame>Measured through Month 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of serious adverse events (SAEs)</measure>
    <time_frame>Measured through Month 12</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">5500</enrollment>
  <condition>Ebola Virus Disease</condition>
  <arm_group>
    <arm_group_label>Ad26.ZEBOV (rHAd26) vaccine + MVA-BN-Filo (MVA) boost</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the Ad26.ZEBOV (rHAd26) vaccine at Day 0 followed by an MVA-BN-Filo (MVA) boost at Day 56.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (0.5 mL)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo at Day 0 followed by a placebo boost at Day 56.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rVSVΔG-ZEBOV-GP (rVSV) vaccine + placebo boost</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the rVSVΔG-ZEBOV-GP (rVSV) vaccine at Day 0 followed by a placebo boost at Day 56.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rVSVΔG-ZEBOV-GP (rVSV) vaccine + rVSV boost</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the rVSVΔG-ZEBOV-GP (rVSV) vaccine at Day 0 followed by an rVSV boost at Day 56.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (1 mL)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo at Day 0 followed by a placebo boost at Day 56.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ad26.ZEBOV</intervention_name>
    <description>0.5 mL at a dose of 5x10^10 vp administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children</description>
    <arm_group_label>Ad26.ZEBOV (rHAd26) vaccine + MVA-BN-Filo (MVA) boost</arm_group_label>
    <other_name>rHAd26</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MVA-BN-Filo</intervention_name>
    <description>0.5 mL at a dose of 1x10^8 InfU administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children</description>
    <arm_group_label>Ad26.ZEBOV (rHAd26) vaccine + MVA-BN-Filo (MVA) boost</arm_group_label>
    <other_name>MVA</other_name>
    <other_name>MVA-mBN226B</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rVSVΔG-ZEBOV-GP</intervention_name>
    <description>1 mL at a dose of 2x10^7 pfu/ml administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children</description>
    <arm_group_label>rVSVΔG-ZEBOV-GP (rVSV) vaccine + placebo boost</arm_group_label>
    <arm_group_label>rVSVΔG-ZEBOV-GP (rVSV) vaccine + rVSV boost</arm_group_label>
    <other_name>rVSV</other_name>
    <other_name>V920</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.5 mL or 1 mL (depending upon the arm) sterile normal saline administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children</description>
    <arm_group_label>Placebo (0.5 mL)</arm_group_label>
    <arm_group_label>rVSVΔG-ZEBOV-GP (rVSV) vaccine + placebo boost</arm_group_label>
    <arm_group_label>Placebo (1 mL)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rVSV boost</intervention_name>
    <description>1 mL at a dose of 2x10^7 pfu/ml administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children</description>
    <arm_group_label>rVSVΔG-ZEBOV-GP (rVSV) vaccine + rVSV boost</arm_group_label>
    <other_name>rVSVΔG-ZEBOV-GP</other_name>
    <other_name>rVSV</other_name>
    <other_name>V920</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent/assent

          -  Age greater than or equal to 1 year (in the initial phase, which only includes the
             rHAd26/MVA-BN-Filo strategy and matching placebo, only those age &gt; 12 years will be
             enrolled)

          -  Planned residency in the area of the study site for the next 12 months

          -  Willingness to comply with the protocol requirements

        Exclusion Criteria:

          -  Fever greater than 38º Celsius

          -  History of EVD (self-report)

          -  Pregnancy (a negative urine pregnancy test is required for females of child-bearing
             potential, i.e., females who have experienced menarche or who are aged 14 years and
             older)

          -  Positive HIV test for participants less than 18 years of age

          -  Reported current breast-feeding

          -  Prior vaccination against Ebola (self-report)

          -  Any vaccination in the past 28 days or planned within the 28 days after randomization
             (initial vaccination)

          -  In the judgement of the clinician, any clinically significant acute/chronic condition
             that would limit the ability of the participant to meet the requirements of the study
             protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yazdan Yazdanpannah</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut National de la Santé Et de la Recherche Médicale, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abdoul Habib Beavogui</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de Formation et de Recherche en Santé Rurale de Mafèrinyah</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Kieh</last_name>
    <role>Principal Investigator</role>
    <affiliation>Redemption Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bailah Leigh</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Sierra Leone</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre national de formation et de recherche en santé rurale (Maferyniah)</name>
      <address>
        <city>Conakry</city>
        <country>Guinea</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr. Abdoul Habib Beavogui</last_name>
      <email>beavoguia_h@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Landreah</name>
      <address>
        <city>Conakry</city>
        <country>Guinea</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pauline Michavila</last_name>
      <email>guinee.respsitecnk.prevail@alima-ngo.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Redemption Hospital</name>
      <address>
        <city>Monrovia</city>
        <country>Liberia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sarah Browne</last_name>
      <email>brownsarah2006@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Guinea</country>
    <country>Liberia</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 15, 2017</lastchanged_date>
  <firstreceived_date>August 16, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ebola Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Hemorrhagic Fever, Ebola</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
